Angion Biomedica Corp reports results for the quarter ended in September - Earnings Summary

Elicio Therapeutics

15/11/2022 09:05

* Angion Biomedica Corp  ANGN.OQ  reported a quarterly
adjusted
loss of 30 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 36 cents per share.
    * Reported revenue was zero​; analysts expected $816.67
thousand. 
    * Angion Biomedica Corp's reported EPS for the quarter was a
loss
of 30 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Angion Biomedica Corp shares had fallen by 2.2% this
quarter and
lost 69.0% so far this year.
    * The company reported a quarterly loss of $8.99 million.
    * Wall Street's median 12-month price target for Angion
Biomedica
Corp is $1.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
15 at 09:05 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.36          -0.30          Beat
 Jun. 30 2022      -0.46          -0.30          Beat
 Mar. 31 2022      -0.43          -0.48          Missed
 Dec. 31 2021      -0.62          0.58           Beat